Put companies on watchlist
Medios AG
ISIN: DE000A1MMCC8
WKN: A1MMCC
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Medios AG · ISIN: DE000A1MMCC8 · EQS - Company News (78 News)
Country: Germany · Primary market: Germany · EQS NID: 1936137
01 July 2024 09:32AM

Medios hosts symposium on 'Security of supply”



EQS-Media / 01.07.2024 / 09:32 CET/CEST

Press release

“Hauptstadtkongress 2024”: Medios hosts symposium on "Security of supply”

Berlin, July 01, 2024 – Medios AG, a leading provider of Specialty Pharma in Europe, was represented for the first time at the “Hauptstadtkongress” (Capital Congress) in Berlin, which took place from June 26 to June 28, 2024 and was dedicated to the key topic of "Advancing the healthcare system". With the symposium on the topic of "Security of supply for seriously ill people – are all players pulling in the same direction?", Medios initiated a multi-faceted dialog with various experts. The “Hauptstadtkongress” is the most important congress event in the German healthcare market and attracts more than 4,000 visitors every year.

Christoph Prußeit, Chief Innovation Officer of Medios AG, was joined by Thomas Weigold (Country President Sandoz Germany & CEO Hexal AG), Dirk Düvel (spokesman for the owners of "wir leben" pharmacies), Dr Klaus Gehring (specialist physician in neurology and psychiatry) and Markus Teuber (VP Partnerships, DasLab GmbH) to discuss the structural challenges of patient care for seriously or chronically ill people in Germany. Due to the diverse backgrounds of the panelists, the symposium offered a comprehensive insight into the high relevance, current situation and development opportunities of specialized care.

Christoph Prußeit, Chief Innovation Officer of Medios AG: „Healthcare in Germany is facing significant challenges. Insolvent hospitals, a shortage of qualified staff and the economic deficits of health insurance companies are placing a heavy burden on the sector and are also affecting outpatient care. In the Specialty Pharma sector in particular, it is our duty to ensure safe and comprehensive care. To achieve this, optimal cooperation between all players along the care chain – from the supplier to the dispensing pharmacy – is essential.”

Dirk Düvel, spokesman for the owners of "wir leben" pharmacies: „Specialized care is associated with both high demands and a high level of responsibility. In order to ensure comprehensive care, all stakeholders involved need to work together effectively. In partnership with Medios, more and more pharmacies in Germany can become involved in specialized care and thus significantly improve the effectiveness and efficiency of care. This is of enormous relevance, particularly in view of demographic change and the associated increase in the number of serious illnesses.“

Every year at the “Hauptstadtkongress”, experts from various fields of healthcare discuss important reform projects and set the course for the modernization of the healthcare system. The “Hauptstadtkongress 2024”, which took place from June 26 to June 28 at hub27, Messe Berlin, focused on the further development of the healthcare system. Three specialist congresses were held under the roof of the “Hauptstadtkongress”: the “Gesundheitsmanagementkongress” (Health Management Congress), the “Pflegemanagementkongress” (Nursing Management Congress) and the “Ärzteforum” (Doctors' Forum). There was also the “Hauptstadtforum Gesundheitspolitik“ (Capital City Health Policy Forum), which also included the Medios symposium.

Further information on the “Hauptstadtkongress 2024” is available here.

-------------------

About Medios AG
Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany's first listed specialty pharmaceutical company and is listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.ag
www.medios.ag



End of Media Release


Issuer: Medios AG
Key word(s): Health

01.07.2024 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Medios AG
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: +49 30 232 566 - 801
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1936137

 
End of News EQS Media

1936137  01.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1936137&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Medios AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.